Unknown

Dataset Information

0

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.

ABSTRACT: BACKGROUND:We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. METHODS:Enrolled patients were treated with 300 ?g of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. RESULTS:Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. CONCLUSION:This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN.

SUBMITTER: Voskens CJ 

PROVIDER: S-EPMC3725741 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

<h4>Background</h4>We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a "penetrin" peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled.<h4>Methods</h4>Enrolled patients  ...[more]

Similar Datasets

Unknown Engineering Vaccines to Reprogram Immunity against Head and Neck Cancer.
| S-EPMC5960883 | biostudies-literature
Unknown A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
| S-EPMC4381442 | biostudies-literature
Unknown Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma.
| S-EPMC3916129 | biostudies-other
Unknown HPV Associated Head and Neck Cancer.
| S-EPMC4999784 | biostudies-literature
Unknown HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.
| S-EPMC3400011 | biostudies-literature
Unknown Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers.
| S-EPMC3028875 | biostudies-literature
Unknown HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer.
| S-EPMC7033022 | biostudies-literature
Unknown Identification of human papillomavirus (HPV) 16 DNA integration and the ensuing patterns of methylation in HPV-associated head and neck squamous cell carcinoma cell lines.
| S-EPMC5877459 | biostudies-literature
Unknown Induction of Trained Immunity by Recombinant Vaccines.
| S-EPMC7873984 | biostudies-literature
Unknown Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas.
| S-EPMC6973261 | biostudies-literature